According to a recent news release from Nasdaq News Service, Aduro Biotech has just announced the results of Phase 1b mesothelioma trials for its new immunotherapy drug, CRS-207.
Phase 1b is part of the process of clinical trials to test new medications on human patients. In this phase, multiple increasing dose studies are performed on human patients to determine safety and tolerability. The patients are given multiple low doses of the drug during the study, and multiple tests are performed to determine how the human body processes the new drug. In the next group of patients, the dose of the experimental drug is increased, and then increased again in future groups, until a preset limit has been reached. Continue reading